Neuroendovascular Coil Market Size & Share 2025 - 2034

Neuroendovascular Coil Market Size

The global neuroendovascular coil market size was valued at USD 1 billion in 2024 and is projected to exhibit 6% CAGR from 2025-2034. The growing prevalence of brain aneurysms and ischemic strokes propels the growth of the market. According to the World Health Organization (WHO), stroke is the second most common cause of death worldwide, accounting for about 11% of all deaths. The Centers for Disease Control and Prevention (CDC) states that nearly 795,000 individuals in the U.S. have a stroke annually. The aging population, coupled with increasing risk factors like hypertension, diabetes, and smoking, has contributed to the increased number of cerebral aneurysm diagnoses.

Approximately 6.8 million people in the US have an unruptured brain aneurysm, or 1 out of every 50 people, according to the Brain Aneurysm Foundation. This has driven demand for minimally invasive treatment like neuroendovascular coiling, which spares rupture and reduces neurological injury or risk of death. The rising prevalence of these disorders has resulted in a high demand for treatment solutions for the neuroendovascular field.
 

The improvements in coil material, design and delivery systems have made endovascular therapy safer, accurate and more effective. Nearly all the new coiling systems received FDA clearance showing how rapidly and significantly the technology is evolving. The coils currently available are more conformable, detachable, and radiopaque, and they can effectively embolize aneurysms, even with challenging vascular anatomy. According to the National Institutes of Health (NIH), endovascular coiling exhibits a lower risk of procedural complications compared to traditional surgical approaches. These technologies have increased physician adoption of endovascular coiling over traditional surgical clipping, indicating the increased confidence in such advanced treatment technologies.
 

Doctors and patients alike are fond of minimally invasive treatments due to faster recovery times, less risk associated with procedures, and reduced hospital stays. Endovascular treatment for initial treatment of the majority of intracranial aneurysm types is what American Heart Association/American Stroke Association guidelines recommend. Neuroendovascular coiling provides a non-surgical method of aneurysm treatment. Evidence within the National Library of Medicine shows that endovascular coiling-treated patients tend to have shorter in-hospital stays, from 2-4 days compared to 5-10 days for surgical clipping. Shifting of the global healthcare system towards value-based care and better patient results has greatly contributed to increased endovascular coil utilization, demonstrating the medical procedure's compatibility with today's healthcare priorities.
 

Neuroendovascular Coil Market Trends

• The use of bioactive and hydrogel-coated coils is growing faster than bare platinum coils in the market. Bioactive and hydrogel coated coils promote aneurysm occlusion by stimulating the body’s healing response or expanding after placement to fill the aneurysm sac.
   
• The improved long-term clinical outcomes and lower rates of recurrence have convinced physicians to employ these newer generation coils in both complicated and straightforward procedures.
   
• The combination of real-time imaging and surgical navigation systems with endovascular coil procedures is revolutionizing neurointerventions. Modern real-time 3D rotational angiography and road-mapping technologies allow procedures to be carried out more accurately and safely while adding additional context when viewing vascular anatomy.
   
• Therefore, these advancements have decreased overall procedure times, while allowing for more accurate coil trajectory path, increased patient safety and improved success rates, leading to the increased demand for technology-enhanced solutions.
   
• Neuroendovascular procedures are gaining traction in the Asia-Pacific, Latin America and Middle East region due to investment in infrastructure and technology. The establishment of stroke centers, greater availability of trained neurosurgeons, and greater public awareness of the importance of rapid and accurate diagnosis and treatment of a cerebral aneurysms has positively impacted the landscape to allow for earlier diagnosis and thus a greater opportunity for better treatment outcomes. The upside opportunity of modern technology in the fields of not only diagnostic but also interventional procedures in the region will only grow.
   

Neuroendovascular Coil Market Analysis

Based on type, the market is segmented into bare platinum coils, hydrogel-coated coils, and other types. The bare platinum coils segment dominated the market with the largest revenue share of 52.8% in 2024.
 

• Bare platinum coils continue to be widely utilized because they have established clinical provenness in treating intracranial aneurysms. Once placed, these coils witness reliable aneurysm occlusion (even with aging). In terms of complication rates, the number of adverse events associated with bare platinum coils has remained low over decades of clinical experience.
   
• There is no comparison for these coils in terms of overall experience and reliability, which is why the use of bare platinum continues even in non-traditional cases, calling for increased demand in both developed and emerging markets for neurointerventions.
   
• The price point of bare platinum coils offers a unique market advantage in healthcare environments that are price-sensitive and where it is common for reimbursements not to exist. These coils provide a satisfactory form of treating aneurysms at a lower price than bioactive or coated alternatives. This price point allows insertion in public hospitals and places where there are limited resources to purchase medical supplies.
   
• Additionally, due of their lower price point than bioactive or coated choices, there is more access to treatment options, especially in less developed healthcare systems that are bound by budgets.
   
• Therefore, the aforementioned factors are expected to significantly boost segment growth over the forecast period.
   

Based on application, the neuroendovascular coil market is segmented into intracranial aneurysms, arteriovenous malformation, and other applications. The intracranial aneurysms segment dominated the market with the largest revenue of USD 760.4 million in 2024.
 

• The worldwide incidence of intracranial aneurysms is projected to continue to climb due to the aging population, lifestyle-related risk factors, and in part due to increased access to imaging modalities and technologies like MRI and CT angiography. The National Institute of Health (NIH) estimates the global mean prevalence of unruptured intracranial aneurysms (UIAs) is approximately 2.8% among the adult population.
   
• As diagnostic imaging continues to rise, patients are getting diagnosed earlier for ruptured and unruptured intracranial aneurysms exposing the need for neuroendovascular coils to treat patients with ruptured and unruptured aneurysm, as well as other minimally invasive treatment options for aneurysms.
   
• Neuroendovascular coiling is expected to become the mainstay of treatment for patients withp intracranial aneurysms since it has lower risk, shorter length of stay, and quicker recovery compared to surgical clipping. The methodology of neuroendovascular coiling is a minimally invasive approach to treat dissecting aneurysms which is especially appealing to older or higher-risk surgical patients.
   
• Therefore, the amalgamation of clinical benefits and as endovascular experience and institutional commitments grow, we can expect changes in practice patterns.
   
• Hence, the aforementioned factors are expected to boost segment growth over the forecast period.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the neuroendovascular coil market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and academic and research institutes. The hospitals segment dominated the market with a share of 69.1% in 2024.
 

• Hospitals around the globe are beginning to build dedicated units for stroke and neurovascular care in response to the increasing number of cerebrovascular diseases. These units are designed to perform time-sensitive procedures, such as aneurysm coiling, and are dependent on a steady supply of neuroendovascular coils.
   
• Expanding focus on neurological care along with increased emphasis on preventing post-stroke complications has increased institutional demand for advanced coiling devices.
   
• In high-income countries, private insurance providers and public healthcare systems have supportive reimbursement policies for hospital -based endovascular therapies.
   
• Healthcare payer coverage limits some of the burden on hospitals and allows for new investments in neurointerventional technologies like embolization coils. The reimbursement paradigm supports hospitals to implement coiling as a standard treatment for an aneurysm and continues to create demand through healthcare systems.
   
• Therefore, the aforementioned factors are expected to significantly boost segment growth over the forecast period.

The North America neuroendovascular coil market was valued at USD 468 million in 2024 and is expected to grow at a CAGR of 5.9% over the forecast period. The market is driven by the increasing incidence of aneurysms across the region.
 

The U.S. market is projected to grow significantly from USD 427 million in 2024 to USD 752.2 million by 2034.
 

• Based on data gathered from the Brain Aneurysm Foundation, roughly 30,000 people in the U.S. experience a brain aneurysm rupture every year. A brain aneurysm ruptures every 18 minutes, and along with the significant incidence of cerebrovascular diseases, this contributes to a high volume of demand for neuroendovascular coils and the need to develop neurointerventional techniques.
   
• The large network of specialized stroke centers, designated neurosurgical sites, and designated interventional radiologic departments in the U.S. facilitate high volume inpatient neuroendovascular procedures.
   
• This great landscape of healthcare facilities promotes the spread of neuroendovascular coils, and new coiling technologies over time. The uptake of these technologies and products sustains market growth.
   
• Therefore, the aforementioned factors are expected to significantly boost regional growth over the forecast period.
   

Europe neuroendovascular coil market was valued at USD 263.9 million in 2024 and is expected to grow at a CAGR of 5.7% over the forecast period.
 

• The network of certified stroke centers and neurovascular units is growing in Europe and especially in Germany, France, and the UK. The centers have neurointerventional capabilities and specialists who can perform aneurysm coiling exocorally.
   
• The national commitment on the part of governments towards managing efficient stroke response and managing aneurysms is serving to increase the demand for neuroendovascular coils to enter the European hospital systems.
   
• European countries are funding and adopting policies aimed at supporting the use of minimally invasive medical technologies so-called endovascular coils. The public hospitals are being encouraged through national health programs and purchasing programs at the public hospital level to transition from surgical clipping and clipping procedures to coil embolization procedures, which offer safety and a greater economic benefit to replacing the surgical inpatient costs. Through this policy, coiling technologies will be common and general in nature to Europe.
   

The neuroendovascular coil market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The UK government is committed to transforming stroke care and neurovascular services by investing in the NHS across the country. The formation of stroke networks and thrombectomy centres, and the establishment of neurointerventional hubs, will help to address the regional variation in treatment.
   
• The NHS is paying for procedures that yield better outcomes at a lower cost. This is how neuroendovascular coiling, which is a minimally invasive procedure and typically results in a shorter length of stay than surgical clipping, fits these criteria.
   
• Within the confines of the NHS budget, the effectiveness and safety of coiling continues to lead hospitals to this treatment for appropriate cases of aneurysm, while still exhibiting consistent demand in the UK.
   
• Hence, the above-mentioned factors are propelling the market growth in the region.
   

The Asia Pacific neuroendovascular coil market is expected to grow at the fastest CAGR of 6.7% over the forecast period.
 

• The growing number of patients is placing increasing pressure on the need for treatment from the health system. The increase in neurological cases related to aneurysms has prompted hospitals and health systems to invest in their neurointerventional requirements and contain adequate stocks of endovascular coils, particularly for the treatment of minimally invasive, emergency cases. The increase in stroke incidence and the simultaneous demand for treatment will persistently require advances in neuroendovascular devices in the region.
   
• China, India and Indonesia have focused on improving their healthcare systems through the development of stroke-ready hospitals and specialized neurosurgical units.
   
• Together with government health reforms and public-private partnerships, a greater availability of infrastructure will allow for greater uptake of neuroendovascular procedures. Greater regional access to advanced care, in turn, improves the demand for neuroendovascular coils across urban centers and second-tier cities.
   

Japan neuroendovascular coil market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The Japan region is witnessing a rise in stroke and cerebral aneurysm cases linked to an ageing population, urbanization, hypertension, and smoking. The Journal of Stroke and Cerebrovascular Diseases states that nearly 270,000 strokes occur in Japan annually, and 120,000 deaths occur due to these strokes.
   
• Additionally, the country is witnessing significant increase in foreign healthcare investment, resulting in the development of advanced infrastructure and developments.
   
• Therefore, the aforementioned factors are expected to significantly boost segment growth over the forecast period.
   

Brazil neuroendovascular coil market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Brazil is experiencing high stroke and cerebral aneurysm rates, which have been increasing in adults aged 55 years as a result of hypertension, diabetes, and smoking. The NIH states that stroke is the greatest cause of death and disability in Brazil, with around 100,000 deaths from stroke each year.
   
• The demographic change is increasing the need for prompt, minimally invasive interventions. The endovascular coiling will likely work best for the patient because it has shorter recovery times and underside risks (compared to neurosurgery) and also complies with the WHO recommendations regarding the management of stroke patients requiring intervention.
   
• Brazil is developing its capability for neurosurgery and stroke intervention through the Sistema Único de Saúde (SUS), as well as regional and federal hospitals. The increasing investment into neurointerventional equipment and training by the federal government will expand access to endovascular treatments in public hospitals and coiling procedures for populations in Brazil.
   
• The consequences of expanding services into under serviced populations will fuel sustainable growth through neuroendovascular coil demand in Brazil's public healthcare sector.
   
• Therefore, the aforementioned factors are expected to significantly boost regional growth over the forecast period.
   

Middle East and Africa: The Saudi Arabia neuroendovascular coil market is expected to experience significant and promising growth from 2025 to 2034.
 

• Increasing lifestyle diseases in Saudi Arabia such as hypertension, diabetes, and obesity are resulting in more intracranial aneurysms and strokes. The International Diabetes Federation reports that the prevalence of diabetes in Saudi Arabia was 17.7% in 2021.
   
• These diseases also affect increasingly younger populations, resulting in earlier onset of disease and a larger patient population in need of neurointerventional care. As this stroke burden grows and the risk factors in the population increase, so does the demand for endovascular coiling treatments. Advanced neurovascular interventions are of upmost importance to public health management in the Kingdom.
   
• Saudi Arabia's Vision 2030 initiative is investing heavily not only in a healthcare infrastructure, but also to focus on specialized care in neurology and interventional radiology.
   
• By building new hospitals and upgrading existing tertiary care hospitals with state of the art healthcare technologies including complex neuroendovascular systems, neuroendovascular treatments including cerebral aneurysm coiling will be much more broadly accessible. This modernization program will lead to higher demand for neurosendovascular coils throughout the Kingdom.
   
• Therefore, the aforementioned factors are expected to significantly boost market growth in the region over the forecast period.
   

Neuroendovascular Coil Market Share

The market has a dynamic mix of international and domestic players providing innovative solutions to meet the growing demand for advanced products for the growing patient population. Companies such as Medtronic, Terumo, Stryker, Penumbra, and Balt are some of the dominant competitors in the market accounting for a combined market share of approximately 75%. Competition in this area arises from continuous technological developments and the ability to offer customized solutions. In developing nations, due to the priority given to cost, multinational companies are squeezed to offer neuroendovascular coils that are both affordable and of quality. Domestic manufacturers take advantage of this demand by providing cost effective alternatives, which make multinationals alter their price strategy while maintaining the safety, ruggedness, and regulatory acceptability of the products.
 

Neuroendovascular Coil Market Companies

Some of the eminent market participants operating in the neuroendovascular coil industry include:

• Acandis
• Allium Medical
• Balt
• Boston Scientific
• Cardinal Health
• Cook Medical
• Kaneka
• Medtronic
• MicroPort
• MicroVention
• Penumbra
• Rapid Medical
• Shape Memory Medical
• Stryker
• Terumo
   
• Medtronic is a major company within the neuroendovascular coil products market with its Axium Detachable Coil System. The system has excellent detachment control, and coil shape and size options for customized treatment of aneurysms. Clinical evidence of the Axium system comes from the ATLAS and MAPS trials which show durability and safety of the detachment system.
   
• MicroVention is another provider of coils, with its HydroCoil Embolic System, which has hydrogel-coated coils that promote fibrosis to reduce recanalization of the aneurysm and improve occlusion rates. In addition, the Target Detachable Coils provide softness and conformability while reducing trauma to the vessel with stable packing of coils.
   
• Stryker's Target Coil System detaches in 360 degrees and uses platinum coils to help control to fill aneurysm. The company's portfolio has a variety of products to support both stroke and aneurysms including the Synchro2 microwire and Trevo stent retriever.
   

Neuroendovascular Coil Industry News:

• In February 2025, Penumbra announced the launch of the Access25 delivery microcatheter. Access25 was introduced as a single-lumen device designed to assist physicians in accessing the neurovasculature for the delivery of Penumbra’s 0.020-inch coil platform. This launch strengthened Penumbra’s neurovascular product portfolio and enhanced its position in the minimally invasive treatment segment.
   
• In December 2024, Kaneka Corporation acquired EndoStream Medical Ltd., an Israeli medical device company. By combining Kaneka’s manufacturing capabilities with EndoStream’s technology, the two companies planned to jointly develop new medical devices, primarily focused on cerebrovascular treatments, in addition to the Nautilus device for aneurysm treatment that was already under development.
   
• In December 2022, Stryker announced that it had received 510(k) clearance for the Target Tetra Detachable Coil. The Target Tetra Detachable Coil featured a new tetrahedral shape and a refined level of softness, specifically designed for the treatment of small aneurysms. This regulatory approval further strengthened Stryker’s neurovascular portfolio and reinforced its leadership in the treatment of complex aneurysms.
   

The neuroendovascular coil market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

By Type

• Bare platinum coils
• Hydrogel-coated coils
• Other types

By Application

• Intracranial aneurysms
• Arteriovenous malformation
• Other applications

By End Use

• Hospitals
• Ambulatory surgical centers
• Specialty clinics
• Academic and research institutes

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific 
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE